Canaccord Genuity Maintains Buy on Definium Therapeutics, Raises Price Target to $64

Benzinga · 2d ago
Canaccord Genuity analyst Sumant Kulkarni maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $58 to $64.